Sarah Cannon Research Institute | Strategic Alliance Partners

Meredith Pelster, MD, MSCI, discusses phase 2a data for atebimetinib plus chemotherapy and the design of a phase 2 trial in pancreatic cancer.

Experts unpack key melanoma data shared during the 2026 ASCO Annual Meeting.

Ahead of the 2026 ASCO Annual Meeting, results from the final analysis of the phase 3 KEYNOTE-522 study have been released.

Experts spotlight the triple-negative breast cancer abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.

Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HER2+ breast cancer, pancreatic cancer, colorectal cancer, and melanoma.

The FDA approved vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after at least 1 line of endocrine therapy.

Drs Rhodes and Patel highlight how the chronic lymphocytic leukemia treatment paradigm continues to evolve with advances in targeted therapy.

Breast oncology experts discuss SABCS 2025 data from HER2CLIMB-05 and lidERA that may influence maintenance therapy and adjuvant endocrine care.

Tucatinib plus HP improved median investigator-assessed PFS by 8.6 months as first-line maintenance vs HP alone in HER2-positive metastatic breast cancer.

Drs Lee and Joseph discuss the significance of the FDA approval of linvoseltamab for the treatment of patients with relapsed/refractory multiple myeloma.

Erika Hamilton, MD, discusses data for vepdegestrant vs fulvestrant in ER-positive, HER2-negative advanced breast cancer.

David Spigel, MD, discusses evaluating the utility of adjuvant chemotherapy in patients with stage IA to IIA NSCLC identified as high risk by a 14-gene molecular assay.

Zanidatamab/chemotherapy showed early antitumor activity with a manageable safety profile in patients with HER2-expressing metastatic breast cancer.

Erika P. Hamilton, MD, discusses the current role of CDK4/6 inhibitors and evolving targeted therapies in advanced HR-positive, HER2-negative breast cancer.

Erika P. Hamilton, MD, discusses how mutational profiles inform the management of HR-positive breast cancer after progression on a prior CDK4/6 inhibitor.

Melissa L. Johnson, MD, discusses the evolution of immunotherapy approaches beyond PD-1 inhibition in lung cancer.

Benjamin Garmezy, MD, discusses the rationale for developing zelenectide pevedotin in metastatic urothelial carcinoma.

Minoo Battiwalla, MD, MS, discusses both the benefits and the limitations of treatment with CAR T-cell therapy across hematologic malignancies.

Minoo Battiwalla, MD, MS, discusses the potential of FLT3-ITD and menin inhibitors to broaden the acute myeloid leukemia treatment paradigm.

Minoo Battiwalla, MD, MS, discusses the variety of bispecific antibodies evaluated for patients with NHL, including DLBCL.

Meredith McKean, MD, discusses the efficacy of fianlimab given in combination with cemiplimab for patients with advanced melanoma.

Treatment with belrestotug plus dostarlimab yielded a clinically meaningful improvement in ORR vs dostarlimab monotherapy in unresectable PD-L1–high NSCLC.

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ESMO Congress.

Erika P. Hamilton, MD, discusses the safety profile of ADCs in patients with hormone receptor–positive, HER2-low and -ultralow breast cancer.

Minoo Battiwalla, MD, discusses remaining unmet needs for patients with multiple myeloma and potential strategies being explored to address these needs.

Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, share their perspectives on the future landscape of HR+/HER2- locally advanced or metastatic breast cancer treatment and provide essential insights to summarize the key points of their discussion.

Medical experts address the challenges of managing adverse events in the treatment of HR+/HER2- locally advanced or metastatic breast cancer.

Recent studies of novel mTOR inhibitors in combination with various agents have shown how these combinations may be used for patients with solid tumors.

Key opinion leaders discuss other clinical trials, including the EMERALD study, and targeted therapies for the treatment of HR+/HER2- locally advanced or metastatic breast cancer in later lines of therapy.